



This is a repository copy of Quality of life in children and young people with congenital adrenal hyperplasia in the United Kingdom - nationwide multicentre assessment.

White Rose Research Online URL for this paper: https://eprints.whiterose.ac.uk/179186/

Version: Published Version

## **Proceedings Paper:**

Lawrence, N.R. orcid.org/0000-0002-7686-6172, Bacila, I.-A., Mahdi, S. et al. (16 more authors) (2021) Quality of life in children and young people with congenital adrenal hyperplasia in the United Kingdom - nationwide multicentre assessment. In: Journal of the Endocrine Society. Annual Meeting of the Endocrine Society (ENDO 2021), 20-23 Mar 2021, Virtual meeting. Oxford University Press , A720-A720.

https://doi.org/10.1210/jendso/bvab048.1465

#### Reuse

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long as you credit the authors, but you can't change the article in any way or use it commercially. More information and the full terms of the licence here: https://creativecommons.org/licenses/

### Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



## Pediatric Endocrinology PEDIATRIC ENDOCRINOLOGY: ADRENAL, THYROID, AND GENETIC DISORDERS

Quality of Life in Children and Young People With Congenital Adrenal Hyperplasia in the United Kingdom - Nationwide Multicentre Assessment Neil Richard Lawrence, MbChB<sup>1</sup>, IRINA-ALEXANDRA BACILA, CLINICAL RESEARCH FELLOW IN PAEDIATRICS<sup>2</sup>, Sundus Mahdi, Bsc, Msc<sup>1</sup>, Sabah Albi, MbChB, MD<sup>3</sup>, Tim D. Cheetham, MD<sup>4</sup>, Elizabeth C. Crowne, MD<sup>5</sup>, Urmi Das, MBBS, MRCPCH<sup>6</sup>, Jeremy Dawson, PhD<sup>7</sup>, Mehul Tulsidas Dattani, DCH, FRCPCH, FRCP, MBBS, MD<sup>8</sup>, Justin Davies, MBBCh, MRCP, FRCPCH, MD<sup>9</sup>, Eveline Gevers, MD, PhD<sup>10</sup>, Ruth Krone, MD<sup>11</sup>, Andreas Kyriakou, MD<sup>12</sup>, Leena Patel, MBBS, MD (India), FRCPCH, MHPEd, MD (Res), SFHEA<sup>13</sup>, Tabitha Randell, PhD<sup>14</sup>, Fiona Ryan, MRCPCH<sup>15</sup>, Brian George Keevil, MSc FRCPath<sup>16</sup>, Syed Faisal Ahmed, MBChB, MD, FRCPCH17, Nils Peter Krone, MD FRCPCH18. <sup>1</sup>SHEFFIELD CHILDREN'S HOSPITAL, Sheffield, United Kingdom, <sup>2</sup>THE UNIVERSITY OF SHEFFIELD, SHEFFIELD, United Kingdom, <sup>3</sup>Great North Children's Hospital, Newcastle, United Kingdom, <sup>4</sup>Dept of Paediatrics, Newcastle upon Tyne, United Kingdom, <sup>5</sup>Bristol Royal Hospital for Children, England, United Kingdom, <sup>6</sup>Alder Hey, Liverpool, United Kingdom, <sup>7</sup>The University of Sheffield, Sheffield, United Kingdom, <sup>8</sup>UCL Institute of Child Health, London, United Kingdom, <sup>9</sup>University Hospital Southampton, Southampton, United Kingdom, <sup>10</sup>Barts Health NHS trust, London, United Kingdom, <sup>11</sup>Birmingham Women and Children's Hospital, Birrmingham, United Kingdom,  $^{12}{\rm Glasgow}$  University, Glasgow, United Kingdom,  $^{13}{\rm University}$ of Manchester, Manchester, United Kingdom, 14Nottingham University Hospitals, Nottingham, United Kingdom, <sup>15</sup>Oxford University Hospitals, Oxford, United Kingdom, <sup>16</sup>Manchester University NHS foundation Trust, Manchester, United Kingdom, <sup>17</sup>Royal Hospital for Children, Glasgow, Scotland, United Kingdom, <sup>18</sup>University of Sheffield, Sheffield, United Kingdom.

Introduction: Impaired Quality of Life (QoL) in Congenital Adrenal Hyperplasia (CAH) has been demonstrated in adults, but research in children has yielded variable results. We investigated the impact of CAH on QoL of children and adolescents alongside clinical health outcomes (biometric and biochemical profiles). Method: We collected data from 14 tertiary UK centres to explore current health status of 8-18 year olds with CAH. QoL was assessed by using three different questionnaires; strengths and difficulties questionnaire (SDQ), Paediatric Quality of life (PedsQL) and Self-image profile (SIP), the former two completed by both patients and their parents. Height, weight and blood pressure were converted to age and sex adjusted z-scores. Serum markers included 170H-progesterone (170HP), androstenedione (D4), testosterone (T) and 11-ketotestosterone (11KT). Statistical Analysis: Statistical analysis comprised of principal component analysis (PCA) followed by multivariate analysis of variance (MANOVA), and post hoc regression. Results: Of the 107 CAH patients included in the study, median age 12.4 years (IQR 10.0-15.1), 55% were female and 104 completed at least 1 questionnaire. Adequate data for PCA was available from 73/107. Three Principal Components (PCs) with observed eigenvalues > 1 explained 71% of the total variance in the observed variables. PC1 reflected 'disease control' comprising 170HP, D4, T and 11KT. PC2 reflected 'biometrics' comprising age, and height and weight z-score. PC3 reflected 'blood pressure', comprising systolic and diastolic z-score. PC1 correlated with outcomes in the parent and patient SDQ as well as parent PedsQL. PC2 and PC3 did not correlate with QoL. Regression analysis revealed higher scores (indicating lower QoL) in the SDQ domain of emotional problems and PedsQL domain of emotional health in patients where biomarkers suggested good control or overtreatment. Post hoc regression analysis revealed a rise in Androstenedione of 10nmol/L equated to an improved SDQ emotional problems score of 0.5 points and an improved PedsQL emotional health score of 3 points. Conclusion: The study found an interrelation between QoL and biomarkers of disease control in CAH. There were more emotional problems with higher levels of androgen suppression. Biochemical control within normal ranges did not predict emotional problems. However, unexpectedly, patients with very high levels of androgens were highlighted as reporting fewer problems with their emotional QoL. Further research into QoL in CAH and optimal levels of biochemical control will further understanding.

# Pediatric Endocrinology PEDIATRIC ENDOCRINOLOGY: ADRENAL, THYROID, AND GENETIC DISORDERS

Relationship Between Iodine Status and Thyroid Function in Preschool Children: From the Environmental and Development of Children (EDC) Study

Yun Jeong Lee, MD¹, You Joung Heo, MD¹, Yunsoo Choe, MD¹, Sang Hee Park, MD¹, Youn-Hee Lim, PhD², Bung-Nyun Kim, MD, PhD³, Johanna Inhyang Kim, MD, PhD⁴, Yun-Chul Hong, MD, PhD⁵, Sun Wook Cho, MD, PhD³, Young Joo Park, MD, PhD⁵, Choong Ho Shin, MD, PhD¹, Young Ah Lee, MD PhD¹.

¹Seoul National University Children's Hospital, Seoul, Korea, Republic of, ²University of Copenhagen, Copenhagen, Denmark, ³Seoul National University Hospital, Seoul, Korea, Republic of, ⁴Hanyang University Medical Center, Seoul, Korea, Republic of, ⁵Seoul National University College of Medicine, Seoul, Korea, Republic of.

Background: We investigated iodine status and its association with thyroid function among preschool children residing in iodine-sufficient area. Methods: From the Environment and Development of Children study, 477 children were evaluated for thyroid function and urine iodine concentration (UIC) at age 6 during 2015-2017. After excluding children born with multiple birth and with congenital hypothyroidism or Hashimoto thyroiditis, 439 (231 boys) were included. Subclinical hypothyroidism (SCH) was defined as thyroid stimulating hormone (TSH) levels between 4.9-10 µIU/mL with normal free T4 levels. Iodine status was evaluated by UIC and children were categorized into 4 groups: iodine deficient (UIC < 100 µg/L), adequate (UIC, 100-299 µg/L), mild excessive (UIC, 300-999 µg/L), severe excessive (UIC ≥ 1000 µg/L). Results: Goiter was palpated in 64 (14.6%) with female predominance (26.0% vs. 4.3%, P < 0.001). Serum level of free T4 and T3 was  $1.2 \pm 0.1$  ng/dL and  $148.1 \pm 18.5$  ng/dL, respectively. The median TSH level was 2.3 (0.53-8.59) µIU/mL and the